SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

TSC-303-A02

TCRX·TScan Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / IND-enabling
Time to market
Preclinical/IND-enabling stage; likely years away from any potential approval if development proceeds.
Why 2/10
No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for TSC-303-A02 in the next ~12 months; the drug is a preclinical/IND-enabling candidate within a pipeline that was radically restructured in September 2026, and the company is focused on survival (reverse split vote, cash runway into Q4 2027).
Actionable Insight NEUTRAL

TSC-303-A02 is an early-stage, preclinical candidate in TScan's new in vivo solid tumor pipeline. The next meaningful event would be an IND filing, which has not been publicly dated. The company's near-term binary is the November 20, 2026 shareholder vote on a reverse stock split to regain Nasdaq compliance. Watch for partnership announcements that could fund further development of the in vivo platform.

Price Chart

Loading chart...

Executive Summary

TSC-303-A02 is a preclinical-stage in vivo TCR-T cell therapy candidate from TScan Therapeutics (TCRX), a micro-cap biotech that underwent a severe restructuring in September 2026. The company cut 75% of its workforce, paused its lead Phase 3 heme malignancy program (TSC-101), and pivoted entirely to early-stage in vivo solid tumor programs targeting PRAME and MAGE-A4. TSC-303-A02 is one of these candidates, still in IND-enabling studies with no clinical data, no regulatory filings, and no dated catalyst. The stock trades around $0.16 with a ~$11.5M market cap and faces a Nasdaq delisting risk. The drug is too early to evaluate on clinical merit and represents a small part of a distressed company's long-shot pivot.

How It Works

TSC-303-A02 is an in vivo-engineered T cell receptor (TCR) T cell therapy designed to target solid tumors. Unlike traditional cell therapies that are manufactured outside the body, this approach aims to engineer a patient's own T cells inside the body to recognize and attack cancer cells expressing specific tumor antigens (likely PRAME or MAGE-A4).

Trial Status

TScan announced in its November 12, 2026 Q3 update that it is advancing PRAME- and MAGE-A4-targeted in vivo TCR-T candidates through IND-enabling studies. TSC-303-A02 appears to be one of these early-stage solid tumor candidates. No clinical trials have been initiated.

The Two-Sided Case

▲ Bull Case3
TScan's strategic pivot to in vivo TCR-T technology targets a potentially disruptive approach that could eliminate complex ex vivo manufacturing, a major hurdle in cell therapy.
The company has cash runway into Q4 2027 (per the September 2026 restructuring) to advance IND-enabling studies for the in vivo solid tumor pipeline.
Analyst consensus still shows 7 Buy/Strong Buy ratings vs 4 Hold (as of November 2026), and the mean price target of $1.00 implies ~495% upside from the current $0.168 price.
▼ Bear Case4
TSC-303-A02 is preclinical with no clinical data, no IND filing date, and no regulatory catalyst visible; the drug is years from any value-inflection event.
TScan is in acute financial distress: stock trades at ~$0.16, market cap ~$11.5M, facing a Nasdaq delisting notice with a reverse split vote scheduled for November 20, 2026.
The company cut 75% of its workforce, terminated its CFO and CMO, paused its only Phase 3 program (TSC-101), and lost its Amgen collaboration -- all in the past few months.
Multiple analysts downgraded the stock in September 2026 (Needham to Hold, Wedbush to Neutral, HC Wainwright to Neutral), and major institutional holders (BlackRock, Marshall Wace, Jane Street) trimmed positions significantly in Q3 2026.

Upcoming Catalysts

  • November 20, 2026: Special shareholder meeting to vote on reverse stock split (1:2 to 1:50) to regain Nasdaq minimum bid price compliance.
  • IND filing for in vivo solid tumor candidates (PRAME/MAGE-A4) -- no date announced.
  • Potential partnership or licensing deal to fund the in vivo platform.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TScan Therapeutics, Inc. 8-K TCRX ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 fiercebiotech.com3 rttnews.com4 marketscreener.com5 quiverquant.com6 seekingalpha.com7 sec.gov8 sec.gov9 sec.gov